Search
Nicotinamide
go.drugbank.com/drugs/DB02701ApprovedInvestigationalMost animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Mixtures: Multivitamin with 1.0 mg Fluoride, MOL-IRON PANEM 500 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of
Mixtures: ZAVİCEFTA 2 G/0.5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 10 ADET, CEFAZIME FOR INJECTION 1 g/vialProducts: Kefazim 500 mg Trockenstechampulle, SEFAVİS 500 MG IM/IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 FLAKON VE 1 AMPULHyperphenylalaninemia Due to 6-Pyruvoyltetrahydropterin Synthase Deficiency (ptps)
smpdb.ca/view/SMP0125585DiseaseBH4-deficient hyperphenylalaninemia has several causes. One such cause is a PTS deficiency resultant from a genetic mutation. (In particular, a mutation in the gene encoding 6-pyruvoyl-tetrahydropterin synthase.) The mutation is autosoma...
Aluminum hydroxide
go.drugbank.com/drugs/DB06723ApprovedInvestigationalIt is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin.
Mixtures: O Hui Veil Fit Dual Foundation 10, DICLOFENACO SÓDICO 100 MG - HIDROXIDO DE ALUMINIO GEL EQUIVALENTE A200 MGProducts: ALU-TAB TABLET 600 MG, ALU-TAB TABLET 600 mgTenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271] … [A178060] Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal
Mixtures: GENVOYA FILM COATED TABLET 150 MG/150 MG/200 MG/10 MG, DESCOVY (200/10 MG)Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLomefloxacin
go.drugbank.com/drugs/DB00978ApprovedAdditionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. … Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: OKACIN GOZ DAMLASI 3 MG/ML 5 ML, LOMFLOX TABLET 400 mgAtogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigational[L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is … A239094] The "gepants" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions to
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: AQUIPTA® 10 MG, AQUIPTA® 60 MGOrnithine
go.drugbank.com/drugs/DB00129ApprovedInvestigationalNutraceuticalProduced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine. L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine.
Mixtures: PEDASEL %10 AMİNO ASİT ÇÖZELTİSİ, 100 ML, PRIMENE %10 İNFÜZYONLUK PEDİYATRİK AMİNOASİT ÇÖZELTİSİ, 100 MLProducts: HEPA-ORNITAT 5 G/10 ML INFÜZYON KONSANTRESI, 10 ADET, HEPALORNİTİN 5 G / 10 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 10 ADETTenecteplase
go.drugbank.com/drugs/DB00031ApprovedInvestigationalIt is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids
Products: METALYSE 10000 U (50 MG) ENJEKSIYONLUK TOZ ICEREN FLAKON, 1 ADET, TENECTEPLASE BOEHRINGER INGELHEIM PHARMA KGTremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth. … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.
Products: Imjudo Concentrate for Solution for Intravenous Infusion 20 mg/mL, Imjudo 300 mg/15 ml İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 adet